10x Genomics AI Stock Analysis
Want to see TXG full AI Analyst Report?
10x Genomics (TXG) AI Stock Analysis
10x Genomics
(NASDAQ:TXG)
TXG scores in the mid-range: improving fundamentals (accelerating revenue, strong gross margins, positive operating/free cash flow, and low leverage) and a constructive earnings call with raised guidance support the score. Offsetting these positives are weak price momentum (below key moving averages with negative MACD) and a valuation profile constrained by continued net losses and no dividend yield data.
10x Genomics Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across different regions, revealing where 10x Genomics is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
10x Genomics' revenue growth in the Americas has been inconsistent, with a recent uptick in Q2 2025, despite a challenging funding environment. Meanwhile, APAC, particularly China, shows strong momentum with a significant year-over-year increase, bolstered by temporary purchasing activity. EMEA's revenue remains stable, but the overall landscape is pressured by declining instrument sales and academic funding challenges. The strategic acquisition of Scale Biosciences and new product launches are expected to drive future growth, though ongoing CapEx constraints and cautious customer spending pose risks.
10x Genomics (TXG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.97B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.36M
- Price to Earnings (P/E)
- -110.3
- Beta (1Y)
- 1.66
- Revenue Growth
- -3.62%
- EPS Growth
- 16.67%
- Country
- US
- Employees
- 1,178
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
10x Genomics Business Overview & Revenue Model
Company Description
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated inst...
How the Company Makes Money
10x Genomics primarily makes money by selling integrated platform workflows that combine capital equipment with recurring consumables. The company’s key revenue streams are: (1) Instrument sales (capital equipment): Revenue from selling or placing in...
10x Genomics Earnings Call Summary
The call was strongly positive overall. Management reported raised revenue guidance, strong consumables performance, growing Atera demand, broad customer interest, expanding AI-related opportunities, improving cash generation and progress across product and clinical initiatives. The main negatives were modest 1% total revenue growth, substantial instrument revenue declines, near-term gross margin compression from the Atera ramp, Apex-related top-line pressure and production and installation constraints.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised its 2026 revenue outlook to the range of $625 million to $635 million, up from $610 million to $630 million, representing 4% to 6% growth over the full year 2025 excluding nonrecurring revenue related to patent litigation settlements in both 2026 and 2025; it now expects to ship approximately 50 Atera instruments by year-end, up from the previous expectation of approximately 40, and said 50 a quarter between those constraints is about the right number going into next year. Gross margins are expected to be in the low to mid-60s for Q4, while 2027 margins will most likely come in lower than where they are because it will be an instrument heavy year and consumables will start to ramp during the course of the year; Spatial consumables in Q4 are expected to still be double digits for sure, with a full quarter of Atera consumables shipments.
10x Genomics Financial Statement Overview
Summary
Financials show an improving trajectory: TTM revenue growth accelerated to +27% with healthy ~72% gross margins, and operating/free cash flow turned solidly positive (~$100M OCF; ~$94M FCF). Balance-sheet risk appears contained with low leverage (debt-to-equity ~0.09) and a sizable equity base. The key offset is that profitability remains negative (TTM net margin about -11%) and cash-flow conversion has shown year-to-year volatility.
Income Statement
52NeutralBalance Sheet
74PositiveCash Flow
67Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 618.58M | 642.82M | 610.78M | 618.73M | 516.41M | 490.49M |
| Gross Profit | 444.65M | 443.88M | 414.48M | 409.31M | 396.02M | 416.40M |
| EBITDA | 44.65M | 3.91M | -133.99M | -205.11M | -128.49M | -24.59M |
| Net Income | -67.08M | -43.54M | -182.63M | -255.10M | -166.00M | -58.22M |
Balance Sheet | ||||||
| Total Assets | 1.06B | 1.04B | 918.64M | 965.14M | 1.03B | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 575.68M | 523.41M | 393.40M | 388.69M | 429.98M | 587.45M |
| Total Debt | 75.79M | 157.74M | 82.61M | 95.37M | 95.18M | 81.98M |
| Total Liabilities | 225.09M | 245.04M | 208.50M | 224.10M | 223.24M | 201.26M |
| Stockholders Equity | 838.04M | 796.33M | 710.13M | 741.04M | 805.74M | 817.57M |
Cash Flow | ||||||
| Free Cash Flow | 93.77M | 130.12M | -5.73M | -64.72M | -165.27M | -122.65M |
| Operating Cash Flow | 99.70M | 136.05M | 6.66M | -15.20M | -33.61M | -21.37M |
| Investing Cash Flow | -11.35M | -13.44M | -32.63M | 133.49M | -350.89M | -106.73M |
| Financing Cash Flow | 5.37M | 6.80M | 10.91M | 13.67M | 15.82M | 35.30M |
10x Genomics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXG, the sentiment is Negative. The current price of 57.38 is below the 20-day moving average (MA) of 65.13, below the 50-day MA of 73.20, and above the 200-day MA of 43.32, indicating a neutral trend. The MACD of -4.67 indicates Positive momentum. The RSI at 39.96 is Neutral, neither overbought nor oversold. The STOCH value of 26.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TXG.
10x Genomics Risk Analysis
10x Genomics disclosed 10 risk factors in its most recent earnings report. 10x Genomics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New Risks10x Genomics Peers Comparison
Overall Rating
TECH74Outperform
ADPT64Neutral
TXG57Neutral
TWST52Neutral
MRVI48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | $11.42B | 66.09 | 8.22% | 0.55% | 0.94% | 122.38% | |
| 64Neutral | $4.54B | -62.04 | -37.40% | ― | 17.91% | 16.01% | |
| 57Neutral | $7.55B | -110.35 | -8.19% | ― | -3.62% | 16.67% | |
| 52Neutral | $7.61B | -53.66 | -23.20% | ― | 22.00% | -60.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $1.87B | -16.14 | -31.86% | ― | 10.77% | 46.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TXG | 10X Genomics | 57.38 | 39.04 | 212.87% | |
| TECH | Bio-Techne | 72.70 | 11.50 | 18.79% | |
| TWST | Twist Bioscience | 111.62 | 83.06 | 290.83% | |
| ADPT | Adaptive Biotechnologies | 28.05 | 9.44 | 50.73% | |
| MRVI | Maravai Lifesciences Holdings, Inc. | 7.19 | 3.44 | 91.73% | |
| ALMR | Alamar Biosciences, Inc. | 28.68 | 6.68 | 30.36% |
10x Genomics Corporate Events
10x Genomics Appoints Two New Directors to Board
NeutralOn October 28, 2026, 10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors, effective immediately. Their terms were set to expire at the company’s 2028 annual meeting of stockholders, unless ended...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
